Soclenicant is being developed by Bionomics.[4] It has also been developed by Ironwood Pharmaceuticals and EmpathBio.[4][5] Bionomics was acquired by Neuphoria Therapeutics in December 2024.[4] As of December 2024, soclenicant is inphase 3clinical trials for anxiety disorders,phase 2 trials for agitation and PTSD, and no recent development has been reported for depressive disorders.[4][5] The drug receivedFast Track designation from theUnited StatesFood and Drug Administration (FDA) in 2019.[8] It was first described in the literature, in aconference abstract, by 2007.[2]
^abcdeHampsey E, Perkins A, Young AH (April 2023). "BNC210: an investigational α7-nicotinic acetylcholine receptor modulator for the treatment of anxiety disorders".Expert Opin Investig Drugs.32 (4):277–282.doi:10.1080/13543784.2023.2192922.PMID36927202.
^abcdAndriambeloson, E., Wagner, S., Huyard, B., Sleebs, B., Quasi, N., Bui, C., ... & Street, I. (2007, September). BNC210: A Novel Compound with Potent Anxiolytic Activity. In Behavioral Pharmacology (Vol. 18, pp. S16–S16).https://neurofit.com/im-posters/2008-ebps-bnc210.pdf
